GeekWire
Menu
  • Home
  • News
    • Amazon
    • Civic presented by Microsoft
    • Geek Life presented by Network of Giving
    • Health/Life Sciences
    • Microsoft
    • Podcasts
    • Space
    • Startups
    • Sustainability
    • Tech Moves
    • Bot or Not
    • GeekWire on the Road: Spokane
    • Microsoft at 50 presented by Accenture
    • Tech Vets presented by Northern Trust
  • GeekWork
    • GeekWork Recruiting
    • Job Board
  • Events
    • Community Calendar
    • GeekWire Events
  • Lists
    • Amazon Office Buildings
    • GeekWire 200 presented by JPMorganChase
    • GeekWire Startup List
    • GeekWire Startup Resources
    • GeekWire Startup Spaces
    • Layoff Tracker
    • M&As and IPOs
    • Northwest Women VC & Angel Investor List
    • Recent Fundings
    • Seattle Engineering Outposts
    • Venture Capital Directory
  • Members
    • Health Benefits
    • Memberships
  • Studios
    • GeekWire Studios: Let Us Tell Your Story
    • Nebius at NVIDIA GTC 2025 sponsored by Nebius
    • AWS Marketplace Seller Conference 2024 sponsored by AWS
    • AWS Summit: New York Partner Spotlights sponsored by AWS
    • Does Compute presented by Carnegie Mellon University
    • Guide to re:Invent sponsored by AWS
    • Money Hacks presented by BECU
    • Tech Connect at Dreamforce 2024 sponsored by RSM US LLP
    • Uncommon Thinkers Welcome sponsored by Greater Seattle Partners
    • Zuper at Inbound sponsored by Zuper
  • About
    • About GeekWire
    • Advertise
    • Contact Us
    • Email Newsletters
    • Reprints & Permissions
    • Sponsors
  • Podcast
  • LinkedIn
  • Newsletter
  • News Tips

What happens here matters everywhere.

  • Podcast
  • LinkedIn
  • Newsletter
  • News Tips
  • Amazon
  • Microsoft
  • Startups
  • AI
  • Science
  • Tech Moves
  • Sustainability
  • Civic
  • Geek Life

Kineta

Seattle biotech company Kineta lays off majority of staff, including its CEO

Kineta announced Thursday that it is laying off 64% of its workforce, or seven employees — including its CEO Shawn… Read More

Tech Moves: Madrona adds three new venture partners; DexCare hires exec; and more

— Seattle venture capital firm Madrona Venture Group announced it added three new venture partners: Loren Alhadeff, Mark Nelson, and… Read More

Seattle biotech company Kineta completes merger, begins trading on Nasdaq

Seattle biotech company Kineta completed its merger with Yumanity Therapeutics, a move that makes Kineta a public company. The combined… Read More

Tech Moves: Glassdoor hires former Convoy chief economist; Kineta adds exec; and more

— Maggie Brady, previously a human resources group leader at fintech company Fiserv, is now head of people at trucking… Read More

Seattle biotech Kineta will go public in deal with neurosciences company Yumanity Therapeutics

Seattle biotech company Kineta is going public through a merger with Yumanity Therapeutics, a neurosciences company based in Boston. Yumanity… Read More

Vote for your favorite Health Innovation of the Year, a new category at the GeekWire Awards

Proteins, algorithms and apps — oh my! Health innovators across the Pacific Northwest continue to embrace technologies that go well… Read More

Biotech startup Kineta inks cancer deal with Pfizer worth up to $505M

Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an… Read More

Kineta signs multi-million dollar collaboration with Genentech to develop non-opioid pain medication

As the U.S. opioid epidemic rages on, the need for effective alternative pain medications is only becoming more acute. Seattle-based… Read More

Biotech startup tries unique weapon in fight against chronic pain and opioid addiction: snail venom

If you didn’t know snails could be venomous, you’re not alone. But it turns out some are, and a recent… Read More

This Seattle biotech startup just secured funding to tackle the Zika virus

Seattle-based biotech startup Kineta announced today that it has received an undisclosed amount of funding to expand research that could… Read More

Kineta wins $7.2M award to develop antiviral drug focused on Lassa fever

Seattle-based biotech startup Kineta today announced that it won a $7.2 million award to develop an antiviral drug therapy for… Read More

Kineta wins $4M award to develop therapies against viral diseases like Ebola, influenza, others

Seattle-based biotech startup Kineta today announced that it won a $4 million federal contract from the National Institute of Allergy and… Read More

Kineta and partners raising funds to ‘break out of the old biotech model’

A consortium that includes Seattle-based biotech company Kineta, UW Medicine, and the University of Washington’s CoMotion group is seeking to raise an… Read More

Seattle biotech firm Kineta raises $1.6 million to boost its battle against disease

Kineta, a Seattle-based biotech startup, has raised an investment round worth almost $1.6 million from existing investors in the company.… Read More

Kineta, UW receive biodefense grant to study ways to wipe out deadly viruses like Ebola

The University of Washington, University of Texas Medical Branch and Kineta — a Seattle biotechnology upstart — have received an… Read More

Latest Stories

    Read All Stories

    GeekWire Newsletters

    Subscribe to GeekWire's free newsletters to catch every headline

    Send Us a Tip

    Have a scoop that you'd like GeekWire to cover? Let us know.

    Send Us a Tip

    A Word From Our Sponsors

    About

    • About GeekWire
    • Contact Us
    • Partner With Us
    • Become a GeekWire Member
    • Send Us a Tip
    • Join Our Startup List
    • Reprints and Permissions

    Follow

    • Facebook
    • X
    • LinkedIn
    • Instagram
    • RSS Feed
    • Podcast
    • YouTube
    • Bluesky

    GeekWire Newsletters

    Catch every headline in your inbox

    Read GeekWire

    • Apple News
    • Google News

    Legal

    • Privacy Policy
    • Terms of Use
    • Sponsored Content Policy
    Return to Top of Page
    © 2011-2025 GeekWire, LLC
    Do Not Sell or Share My Personal information
    Limit the Use Of My Sensitive Personal Information
    Consent Preferences